Penn Cytomics and Cell Sorting Resource Laboratory | |
IntroductionHOMEHow to Request ServiceServices OfferedFees-BillingSite locationsInstrumentation InformationStaff DirectoryAccess PolicyServicesSchedulingBiohazardous Cell SortingBiosafety QuestionnaireRequest trainingFlowJo Subscription ManagerFCS Express Subscription ManagerData retrievalDownload FCS2 converterForms and ProtocolsPay invoicesUser ProfileEducationLinks of InterestFluorochrome SelectorFrequently Asked Questions |
|
While this core will be available to School of Medicine
faculty, Cancer Center members will have priority. The highest priority will
be given to Cancer Center members with either clinical trials approved by the
Clinical Trials Scientific Review and Monitoring Committee or peer-reviewed
funding, followed by Cancer Center members with non-peer reviewed funding. All
investigators will be required to meet with Dr. Moore prior to using the
Facility. This will ensure that the Facility is an appropriate venue for the
proposed research, that the project design incorporates the efficient use of
the Facility, and that the costly resources of the Facility are used for the
greatest scientific benefit. Prioritization of projects will be determined in
consultation with the Advisory Committee as additional trials are proposed,
and will be based upon scientific merit, technical feasibility, Cancer Center
membership, the availability of external funding, and the resource
requirements of the core.
Please be conscientious of the fact that you are operating an expensive piece of equipment that is used for numerous scientific projects. Therefore, any instrument downtime due to careless handling will affect many different investigators. The Core Facility is accessible to all members of the University community with priority access granted to members of the University of Pennsylvania Cancer Center. Only graduates of the flow cytometry classes conducted by the Facility are allowed to operate the flow cytometers under the general supervision of the Facility staff. Approved individuals have 24/7/356 access to the FACScans and FACSCaliburs after demonstrating a required level of proficiency. We do not permit the use of the instruments by users who were not trained directly by Core personnel.
While it is the policy of the Flow Cytometry and Cell Sorting Shared Resource to provide investigators with the tools to perform their own analyses, it is recognized that some applications, including cell sorting, require a high level of expertise and are best performed by the staff. Thus, facility-performed services are offered subject to the following guidelines:
Due to the fact that cell sorting generates aerosols and the cells are generally no submitted in any fixative, the biohazard risks are much greater than in analytical flow cytometry. It is therefore imperative to discuss any and all biohazard issues with the sorter operator. Failure to do so may result in denial of further use of the cell sorting facility. We are equipped to perform sorts on infected/infectious samples, but the sorting or acquisitions of potentially infectious samples must be cleared with the Technical Director, Hank Pletcher. The University of Pennsylvania scientific community has increasingly made use of complex flow cytometric analyses and cell sorting requiring the usage of high-end instrumentation. This has led to a proportionate increase in requests for service and increased the lead-time necessary to schedule these types of applications. It has always been our policy to make service as accessible as possible for all users so we must continuously update our policies to fairly serve the entire research community. In performing an audit of usage over the past 6 months, we determined that cancellations have risen to over 30%. This severely limits access in a timely manner for many users and often results in sorters being unused with a long waiting list. In an effort to better utilize the hours available on the high-end instrumentation for the most users, we have enacted the following policies effective April 1, 2003:
Thank you in advance for your cooperation as we continue to support your research needs. |